Protein Tyrosine Phosphatase Degraders for Diabetes Treatment
Solution Overview
Problem
Current approaches to modulating the ubiquitin-proteasome pathway for therapeutic protein degradation, such as targeting PTP1B for treating type 2 diabetes and obesity, lack effective compounds and methods to fully harness its potential.
Innovation Solution
Development of compounds comprising a Targeting Ligand that binds to protein tyrosine phosphatases like PTPN2 and PTPN1, a Degron that binds to an E3 Ligase, and a linker that covalently links the Targeting Ligand to the Degron, facilitating protein degradation through the ubiquitin proteasome pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint blockade immunotherapy is used to treat cancer, then immune evasion is blocked and treatment effectiveness is improved, but incomplete clinical responses and resistance development occur
Solution Approach 1:
The patent segments the immunotherapy approach by introducing a dual-targeting system: one component blocks PD-1/PD-L1 checkpoint interaction while another component targets PTPN2 for degradation. This segmentation allows simultaneous attack on multiple immune evasion mechanisms, overcoming the limitation of single-target checkpoint blockade and reducing incomplete responses.
Solution Approach 2:
The patent uses PTPN2 as an intermediary target that connects checkpoint blockade therapy to enhanced immune response. By degrading PTPN2, the therapy indirectly amplifies T cell activation and cytokine signaling, serving as a bridge between checkpoint inhibition and improved clinical outcomes, thereby addressing resistance development.
2Reliability
If PTPN2 is degraded to enhance IFNγ signaling and improve immunotherapy response, then treatment efficacy is improved, but the complexity of the degradation mechanism increases
Solution Approach 1:
The patent extracts the essential degradation function into a separate modular component (the degrader molecule) that can be independently designed and optimized. This extracted approach separates the targeting function (binding to PTPN2) from the degradation function (recruiting the proteasome), simplifying the overall mechanism while maintaining efficacy.
Solution Approach 2:
The patent employs a designed degrader molecule that copies and enhances the natural ubiquitin-proteasome degradation pathway. By creating a synthetic ligand that mimics and amplifies physiological degradation signals, the complex natural process is harnessed in a controlled, predictable manner, reducing the perceived complexity.
3Adaptability or versatility
If protein degradation pathways are harnessed for therapeutic purposes, then protein activity is effectively modulated, but the lack of effective compounds limits full potential utilization
Solution Approach 1:
The patent systematically varies key parameters of the degrader molecule including the linker length, linker chemistry, and warhead structure to optimize degradation efficiency and selectivity. By changing these parameters, the patent transforms a theoretical concept into practical, manufacturable compounds with improved properties.
Solution Approach 2:
The patent creates composite degrader molecules by combining distinct functional modules: a PTPN2-binding warhead, a linker, and a degradation-inducing motif. This composite approach integrates multiple functions into a single molecule, making the compound both effective and amenable to manufacturing through modular synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds and methods enhance the degradation of specific proteins like PTPN2 and PTPN1, potentially improving treatment outcomes for conditions like type 2 diabetes and obesity by effectively modulating protein activity.
Implementation Method 1
facilitating protein degradation through the ubiquitin proteasome pathway
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.